Wittycell S.A.S. is a biotechnology company focused on the development of innovative vaccine adjuvants activating the immune system against infectious disease and cancer.

Wittycell adjuvants have the potential to improve established vaccines and to allow the development of new vaccines for diseases that previously would not have been considered as vaccine targets. 

Wittycell is currently developing two types of products, using its proprietary technology platforms:

• Lipid adjuvant products for therapeutic and prophylactic vaccines against
  infectious disease and cancer.
  
• Cellular Adjuvant products for therapeutic vaccines against cancer.

Wittycell S.A.S. has a strong IP position with major partnership including the Jean Godinot Institute, the Scripps Research Institute, the University of Chicago and the Brigham Young University.

The potential market encompasses over 90% of the total new vaccine market which represents over $18 bn market potential.